Back to Results
First PageMeta Content
Medicine / Peptide hormones / Recombinant proteins / Eli Lilly and Company / Insulin therapy / Insulin glargine / Diabetes management / Diabetes mellitus type 1 / Insulin / Diabetes / Endocrine system / Biology


Introduction: Degludec and Degludec/Aspart Endocrinologic and Metabolic Drugs Advisory Committee Meeting November 8, 2012 Jean-Marc Guettier, MDCM
Add to Reading List

Open Document

File Size: 1,25 MB

Share Result on Facebook

Company

DCCT / Novo Nordisk / /

IndustryTerm

diabetes products / insulin products / injectable insulin product / injectable insulin products / /

MedicalCondition

nonfatal myocardial infarction / hypertension / diabetes mellitus / immediately post-myocardial infarction / microvascular disease / stroke / diabetes / /

MedicalTreatment

insulin therapy / /

Organization

New Drugs Center for Drug Evaluation / Metabolism and Endocrinology Product Office / Clinical Team Leader Division of Metabolism / Degludec/Aspart Endocrinologic and Metabolic Drugs Advisory Committee / U.S. Food and Drug Administration / /

Person

Jean-Marc Guettier / /

PublishedMedium

the ORIGIN / /

SocialTag